Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 13/20 | 0.33 |
| ▸ | NPY1R | P25929 | 9/20 | 0.33 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.33 |
| ▸ | NPY2R | P49146 | 5/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21424858 | 0.86 | MEN1 (0.35) | NPY4RNPY1RNPY5RNPY2RMEN1 | |
| SCHEMBL20100649 | 0.83 | ALOX15 (0.34) | NPY4RNPY1RNPY5RNPY2RMEN1 | |
| SCHEMBL21559886 | 0.82 | MEN1 (0.33) | MEN1CYP1A2KMT2ASMN1; SMN2ALOX15 | |
| SCHEMBL20099657 | 0.76 | MEN1 (0.37) | MEN1CYP1A2KMT2ASMN1; SMN2ALOX15 | |
| SCHEMBL21541166 | 0.74 | MEN1 (0.36) | MEN1CYP1A2KMT2ASMN1; SMN2ALOX15 | |
| SCHEMBL7935092 | 0.74 | MEN1 (0.44) | NPY4RNPY1RNPY5RNPY2RMEN1 | |
| SCHEMBL20104611 | 0.74 | ALOX15 (0.34) | MEN1CYP1A2KMT2ASMN1; SMN2ALOX15 | |
| SCHEMBL20763852 | 0.74 | NPY4R (0.41) | NPY4RNPY1RNPY5RNPY2RMEN1 | |
| SCHEMBL21973636 | 0.74 | NPY4R (0.41) | NPY4RNPY1RNPY5RNPY2RMEN1 | |
| SCHEMBL26390131 | 0.74 | ALOX15 (0.32) | NPY4RNPY1RNPY5RNPY2RMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018208-A1 | CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-18 | — | — | US | disclosed |
| US-20230365644-A1 | ANTIBODY-COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-16 | — | — | US | disclosed |
| US-11780900-B2 | Glucagon like peptide 1 (GLP-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereof | Janssen Sciences Ireland Unlimited Company (IE) | 2023-10-10 | — | — | US | disclosed |
| US-10968265-B2 | Antibody-coupled cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors | JANSSEN PHARMACEUTICA NV (BE) | 2021-04-06 | — | — | US | disclosed |
| US-10961293-B2 | Cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors | JANSSEN PHARMACEUTICS NV (BE) | 2021-03-30 | — | — | US | disclosed |
| US-10640544-B2 | Antibody-coupled cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors | JANSSEN PHARMACEUTICA NV (BE) | 2020-05-05 | — | — | US | disclosed |
| US-20190345214-A1 | CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-11-14 | — | — | US | disclosed |
| US-20190298849-A1 | ANTIBODY-COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-10-03 | — | — | US | disclosed |
| US-20180117170-A1 | ANTIBODY-COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10961293-B2 | Cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors | NPY4R, NPY5R, NPY1R | NPY4R 1/4885NPY1R 3/4885NPY5R 2/4885 |
| US-20190298849-A1 | ANTIBODY-COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS | NPY1R, NPY5R, NPY2R | NPY4R 4/4885NPY1R 1/4885NPY5R 2/4885 |
| US-20240018208-A1 | CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS | NPY4R, NPY5R, NPY1R | NPY4R 1/4885NPY1R 3/4885NPY5R 2/4885 |
| US-10640544-B2 | Antibody-coupled cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors | NPY1R, NPY5R, NPY2R | NPY4R 4/4885NPY1R 1/4885NPY5R 2/4885 |
| US-11780900-B2 | Glucagon like peptide 1 (GLP-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereof | GLP1R, GIPR, IAPP | NPY4R 12/4885NPY1R 6/4885NPY5R 13/4885 |
| US-10968265-B2 | Antibody-coupled cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors | NPY1R, NPY5R, NPY2R | NPY4R 4/4885NPY1R 1/4885NPY5R 2/4885 |
| US-20180117170-A1 | ANTIBODY-COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS | NPY1R, NPY5R, NPY2R | NPY4R 4/4885NPY1R 1/4885NPY5R 2/4885 |
| US-20230365644-A1 | ANTIBODY-COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS | NPY1R, NPY5R, NPY2R | NPY4R 4/4885NPY1R 1/4885NPY5R 2/4885 |
| US-20190345214-A1 | CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS | NPY4R, NPY5R, NPY1R | NPY4R 1/4885NPY1R 3/4885NPY5R 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.